title: Cost-effectiveness of cervical cancer prevention.
abstract: Cost-effectiveness analyses are an important tool for the evaluation and modification of many health care services. Given the variety of screening tests and treatments available for cervical cancer screening and prevention, the costs associated with these options and with their alternatives, and the differences in resources and settings in which these tests are applied worldwide, cost-effectiveness analyses evaluation can be very useful to help determine best practices.
authors: Brigham and Women's Hospital, Boston, Massachusetts, USA.
authors: Katharine M
authors: KM
authors: Esselen
authors: Sarah
authors: S
authors: Feldman
mesh_terms: D003362:Cost-Benefit Analysis; D003906:Developing Countries / Q000191:economics; D055088:Early Detection of Cancer / Q000191:economics*; D005260:Female; D061809:Human Papillomavirus DNA Tests / Q000191:economics; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D008390:Markov Chains; D030361:Papillomavirus Infections / Q000175:diagnosis; D053918:Papillomavirus Vaccines / Q000191:economics; D019057:Quality-Adjusted Life Years; D014481:United States; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000517:prevention & control*; D014626:Vaginal Smears / Q000191:economics*
chemical_list: D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18